1,394,217 Shares in Edwards Lifesciences Corporation $EW Acquired by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, Holdings Channel.com reports. The fund acquired 1,394,217 shares of the medical research company’s stock, valued at approximately $126,121,000.

Several other institutional investors have also added to or reduced their stakes in the company. Hanson & Doremus Investment Management bought a new stake in Edwards Lifesciences during the first quarter worth $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at $26,000. RMG Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth $26,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth $27,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on EW shares. Evercore restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Citigroup lifted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. BTIG Research boosted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. UBS Group assumed coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price for the company. Finally, Truist Financial raised their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Up 0.4%

Shares of EW opened at $91.13 on Wednesday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The stock has a market capitalization of $52.47 billion, a price-to-earnings ratio of 52.37, a PEG ratio of 2.30 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock has a fifty day moving average of $88.90 and a 200-day moving average of $84.49.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.